logo
What the science says about artificial food dyes

What the science says about artificial food dyes

Washington Post23-04-2025

The Department of Health and Human Services said Tuesday that it plans to phase out petroleum-based food dyes from the nation's food supply. Robert F. Kennedy Jr., the health secretary, has called the dyes 'poison' and long blamed artificial additives for chronic disease and illness in the United States.
Companies add dyes to food, such as candy, cereals, drinks and snacks, for brighter, attractive colors. The dyes are either natural, such as red beet juice, or synthetic.
'The ingredients used in America's food supply have been rigorously studied following an objective science and risk-based evaluation process and have been demonstrated to be safe,' Melissa Hockstad, the chief executive of Consumer Brands Association, a food industry trade group, said in a statement. 'Removing these safe ingredients does not change the consumer packaged goods industry's commitment to providing safe, affordable and convenient product choices to consumers.'
But consumer advocacy groups said there is sufficient evidence that the dyes may cause some harm to some children. They argue that artificial dyes are not worth the potential risk given their lack of nutritional value.
'From the vantage point of consumers, it boils down to why do we want to take a chance on these things when it comes to the health of our children?' said Brian Ronholm, director of food policy at Consumer Reports. 'Even if it doesn't technically point to causing cancer, there is risk involved in terms of how it impacts neurobehavior in children.'
The Washington Post spoke with food scientists and nutrition experts to answer questions about the synthetic dyes in food.
In January, under the Biden administration, the FDA banned red dye No. 3 in food. The dye, which gives food a cherry-red color, has been linked to cancer in animals.
In 1990, the agency banned the use of the red dye in cosmetics because preliminary animal research suggested a link to thyroid cancer. The FDA has said there's no evidence that ingesting the coloring causes cancer in humans. The agency said its decision was based on a federal law prohibiting additives found to cause cancer in humans or animals at any dose.
In some studies, synthetic food dyes used in the U.S. have been associated with hyperactivity and behavioral effects in children.
In 2021, the Office of Environmental Health Hazard Assessment in California published a review of seven food dyes such as red dye No. 3, red dye No. 40 and yellow dye No. 5. The review concluded that the consumption of food with added dyes is associated with hyperactivity, restlessness and other neurobehavioral problems in some children, though sensitivity can vary.
'They're not needed,' said Alyson Mitchell, a professor and food chemist at the University of California at Davis and a co-author of the California review. 'They don't present the consumer with any benefit. Only a potential risk.'
But some researchers disagreed on whether the existing evidence is conclusive and said it's hard to isolate the effect of one ingredient or additive because we eat a combination of various foods every day.
Research hasn't found a plausible mechanism for how synthetic dyes could affect the behavior of children, and the findings tend to be based on parents' observations 'rather than some strict criteria that wouldn't be subject to bias,' said Ronald Kleinman, physician-in-chief emeritus at Mass General Hospital for Children.
'This is an example where we really don't have any evidence that the natural food colorings are really any better than the synthetic food colorings,' Kleinman said. 'There are so many other things for us to consider in the general health of children that food colorings are way down on the list.'
The FDA has previously said it would examine potential effects of color additives on children's behavior. The 'totality of scientific evidence' indicates that most children do not suffer adverse effects when consuming food colored with the dyes, but some evidence suggests that certain children may be sensitive to them, it said.
The evidence is 'complicated' and 'mixed,' said Marion Nestle, an emeritus professor of nutrition, food studies and public health at New York University. But, she said, 'these dyes are unnecessary.'
'If there's any question at all about whether they might be harmful,' Nestle said, 'let's get rid of them.'
California decided to ban certain artificial dyes in food served in public schools. And in West Virginia, Gov. Patrick Morrisey (R) signed legislation last month banning foods containing seven synthetic dyes in schools from Aug. 1 and foods with the dyes in the state starting in 2028.
Artificial and natural dyes are listed on the ingredients label.
Checking the label is a 'reasonable step' for someone who's concerned about attention-deficit/hyperactivity disorder-like symptoms, or their irritability and mood, said Joel Nigg, a professor of psychiatry at Oregon Health & Science University. A person who reduces their consumption of foods with artificial dyes 'should notice the benefit within a few days,' if it is a factor, he said.
'Food dyes are not a major contributor to ADHD,' Nigg said. 'But they do play a small role in worsening attention and behavior in children.'
For home cooking and baking, natural dyes — extracts from fruits and vegetables — can add color.
The extracts for natural dyes have thousands of compounds and often different flavor profiles, which makes them problematic, Mitchell said. Natural dyes are more challenging for manufacturers to use, and it's not as simple as replacing artificial with natural alternatives.
'Natural does not imply safety,' Mitchell said. 'I have some concerns that we might be replacing one problem with another problem.'
'I think we need to recalibrate our expectation of color in food,' she said.
Marlene Cimons contributed to this report.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Health New England to replace Humira coverage with lower-cost biosimilars
Health New England to replace Humira coverage with lower-cost biosimilars

Yahoo

time3 hours ago

  • Yahoo

Health New England to replace Humira coverage with lower-cost biosimilars

SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of its commercial health plans. Markey playing defense against GOP clean energy plans Effective July 1, the not-for-profit health insurer will cover Amjevita by Nuvaila and Hadlima instead of Humira, as part of a broader effort to manage rising health care costs while maintaining access to effective treatments. Humira is used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. 'Biologic medications like Humira are complex treatments that carry significant cost. Its biosimilars provide a meaningful opportunity to enhance affordability for the health care ecosystem while members continue to get the full benefits of the medication,' said Gary Tereso, PharmD, Director of Pharmacy Services at Health New England. Biologic drugs are made from living organisms and are typically more expensive than other medications. Biosimilars are developed to be nearly identical in safety, potency, and efficacy to the original biologic, but at a significantly lower cost. The shift in coverage is intended to make treatment more accessible and financially sustainable for members and employer groups alike. Health New England is directly reaching out to members who are currently prescribed Humira, along with their health care providers and pharmacies, to assist with the transition. The company said it will continue monitoring the biosimilar marketplace to ensure members receive both high-quality care and cost-effective treatment options. WWLP-22News, an NBC affiliate, began broadcasting in March 1953 to provide local news, network, syndicated, and local programming to western Massachusetts. Watch the 22News Digital Edition weekdays at 4 p.m. on Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members
RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members

Business Insider

time4 hours ago

  • Business Insider

RFK Jr. reconstituting vaccine advisory committee, retiring 17 current members

In an opinion article published by The Wall Street Journal, Robert F. Kennedy Jr. stated: 'Vaccines have become a divisive issue in American politics, but there is one thing all parties can agree on: The U.S. faces a crisis of public trust. Whether toward health agencies, pharmaceutical companies or vaccines themselves, public confidence is waning… That is why, under my direction, the U.S. Department of Health and Human Services is putting the restoration of public trust above any pro- or antivaccine agenda… Today, we are taking a bold step in restoring public trust by totally reconstituting the Advisory Committee for Immunization Practices (ACIP). We are retiring the 17 current members of the committee, some of whom were last-minute appointees of the Biden administration. Without removing the current members, the current Trump administration would not have been able to appoint a majority of new members until 2028… A clean sweep is needed to re-establish public confidence in vaccine science.' Confident Investing Starts Here:

Part D Cancer Drug Launch Prices Soar Past Inflation
Part D Cancer Drug Launch Prices Soar Past Inflation

Medscape

time4 hours ago

  • Medscape

Part D Cancer Drug Launch Prices Soar Past Inflation

Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store